The international community has a golden opportunity to start reining in the escalating, mostly ignored global burden of ...

A review finds gaps in patient-nephrologist communication in advanced kidney disease, including care planning and dialysis, ...

The global burden of chronic kidney disease (CKD) is rising, with more than 800 million people affected worldwide. Vascular diseases in patients with CKD are unique and grouped as uremic vascular ...

The global burden of chronic kidney disease (CKD) is rising, with more than 800 million people affected worldwide. Vascular ...

Post hoc results support the initiation of SGLT2 inhibitors in patients with diabetic nephropathy regardless of iron deficiency. Canagliflozin treatment may improve iron markers and hemoglobin levels ...

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies ...

to reduce the risk of renal failure and cardiovascular death in people with chronic kidney disease (CKD). The new indication could unlock a sizeable new market for Jardiance (empagliflozin), which ...

Shruti Gupta, MD, MPH, and David Leaf, MD, MMSc, of the Renal Division, Department of Medicine at Brigham and Women's ...

There are currently no proven therapies that reduce cisplatin-induced acute kidney injury (AKI) in patients with cancer.

Adding venetoclax to decitabine-cedazuridine significantly enhanced response rates in patients with higher-risk ...

Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn ...